Cell Line News and Research

RSS

DiscoveryBioMed receives NIDDK grant for Cystic Fibrosis Corrector Ligand Drug Discovery program

DiscoveryBioMed, Inc. (DBM), a human cell-based drug discovery company, learned recently that its Cystic Fibrosis Corrector Ligand (CFCL) Drug Discovery program will be funded by the NIH. The two-year award will focus on validation and prioritization of several lead CFCL chemical classes, drugs that correct the most common cystic fibrosis (CF) disease-causing mutation.

14 Sep 2011

Protein that allows Ebola virus to attack cells discovered

A U.S. research team has discovered a protein called Niemann-Pick C1 (NPC1), which they found was responsible for allowing Ebola virus to enter and replicate within cells.

26 Aug 2011

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Although outbreaks are rare, Ebola virus, the cause of Ebola hemorrhagic fever (EHF), is one of the deadliest known viruses affecting humans. According to the World Health Organization (WHO), approximately 1,850 EHF cases with more than 1,200 deaths have been documented since the virus was identified in 1976.

25 Aug 2011

Molecular Endocrinology journal publishes two studies on estrogen hormones

University of Houston (UH) researchers have their sights set on developing possible treatments for breast and colon cancer.

23 Aug 2011

Biochemist develops polymer material to convert precursor cells into functional neurones

Nervous system diseases are especially difficult to treat, as it is not easy to replace the parts of the neural puzzle which are damaged. The key is in developing functional neurons from in vitro-treated, cells but for this it is essential that the support on which these cells are based simulate the characteristics of the nervous system.

16 Aug 2011

Zalicus second quarter revenue decreases to $1.8 million

Zalicus Inc. today reported financial results for the second quarter ended June 30, 2011.

3 Aug 2011

Taxoxifen combined with dasatinib reverses chemo-resistance in breast cancer cells

Taking a leukemia chemotherapy drug may help breast cancer patients who don't respond to tamoxifen overcome resistance to the widely-used drug, new research from the Kimmel Cancer Center at Jefferson suggests.

2 Aug 2011

Nature Biotechnology publishes BGI, GT Life Sciences' study on CHO K1 genome

BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published July 31, 2011 online in Nature Biotechnology.

1 Aug 2011

Carcinogenesis is just another form of speciation, proposes new theory

Cancer patients may view their tumors as parasites taking over their bodies, but this is more than a metaphor for Peter Duesberg, a molecular and cell biology professor at the University of California, Berkeley.

27 Jul 2011

Selexis, CSL enter commercial license agreement for therapeutic antibody

Selexis SA, a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins announced today that CSL Limited has entered a commercial license agreement with Selexis for the preclinical development of a therapeutic antibody anticipated to enter Phase I clinical trials in 2012.

26 Jul 2011

Lonza, Cellectis reach milestone in development of newly bioengineered cell line

Cellectis bioresearch, the genome customization specialist and a commercial subsidiary of Cellectis, and Lonza, a world leader in biotechnology production, announce today that they have reached a significant milestone in the development of a newly bioengineered cell line.

21 Jul 2011

Progesterone could fight against neuroblastoma

High doses of the hormone progesterone can kill neuroblastoma cells while leaving healthy cells unscathed, scientists at Emory University School of Medicine have found in laboratory research.

14 Jul 2011

Indirubin might help treat glioblastoma

The active ingredient in a traditional Chinese herbal remedy might help treat deadly brain tumors, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

13 Jul 2011

Sunshine completes Adva-27a study in Multidrug Resistant Breast Cancer cell line

Sunshine Biopharma Inc., a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.

12 Jul 2011

Sunshine Biopharma completes Adva-27a cytotoxicity study in Multidrug Resistant Breast Cancer cell line

11 Jul 2011

New technique may help scientists probe mysteries of many different stem cells

Researchers at the Salk Institute have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact.

8 Jul 2011

Researchers identify cellular origin of malignant glioma

Using a mouse genetic system co-developed by researchers at the University of Oregon and Stanford University, a research team led by UO biologist Hui Zong has isolated the cellular origin for malignant glioma, a deadly human brain cancer.

8 Jul 2011

Mary Ann Liebert peer-reviewed journal highlights advances in gene therapy for neurological diseases

Novel tools and methods for delivering therapeutic genes to cells in the central nervous system hold great promise for the development of new treatments to combat incurable neurologic diseases.

30 Jun 2011

STSI joins JAX consortium to develop targeted cancer therapies

The Scripps Translational Science Institute (STSI) of San Diego, Calif., has joined a national consortium of research institutions headed by The Jackson Laboratory (JAX) that is building a library of primary human tumors with the goal of developing highly targeted cancer therapies.